Abbott Laboratories (ABT)

$109.02 -0.39 (-0.36%)
Market Cap 190.06B
Revenue (ttm) 44.33B
Net Income (ttm) 6.52B
EPS (ttm) N/A
PE Ratio 20.60
Forward PE 18.67
Profit Margin 14.72%
Debt to Equity Ratio 0.25
Volume 14,645,400
Avg Vol 8,833,454
Day's Range N/A - N/A
Shares Out 1.74B
Stochastic %K 43%
Beta 0.72
Analysts Strong Sell
Price Target $137.54

Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement th...

Industry: Medical Devices
Sector: Healthcare
Phone: 224 667 6100
Address:
100 Abbott Park Road, Abbott Park, North Chicago, United States
MeridianSecurities
MeridianSecurities Feb. 4 at 11:28 AM
$ABT is a diversified healthcare giant with strong diagnostics and medical device businesses; FreeStyle Libre continues to excel.
0 · Reply
MiyagisenseiJr
MiyagisenseiJr Feb. 3 at 2:31 PM
$ABT wtf why is this dumping??
1 · Reply
MargieAdams1042
MargieAdams1042 Feb. 3 at 6:05 AM
$SAN $ABT Global diversification
0 · Reply
anachartanalyst
anachartanalyst Feb. 2 at 4:02 PM
$ABT https://anachart.com/wp-content/uploads/ana_temp/1770048106_soc-img.jpg
0 · Reply
erevnon
erevnon Feb. 2 at 3:11 PM
Barclays maintains Abbott Laboratories $ABT at Overweight and lowers the price target from $169 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Jas45z
Jas45z Feb. 2 at 3:11 PM
$ABT The stock recently touched a low near $105–$106 following its earnings report. Support Level: $105.00 is the critical floor. If it holds here, it forms a "double bottom" (a bullish reversal pattern). Initial Resistance: The first major hurdle is the $113.00 level (the previous low-end target). The Breakout Trigger: A high-volume move above $120.00 (reclaiming its 50-day moving average) would signal that the post-earnings sell-off is over and the primary uptrend has resumed.
0 · Reply
Bazzzigar
Bazzzigar Feb. 2 at 2:56 PM
$ABT few more
0 · Reply
PolycarpFX
PolycarpFX Feb. 2 at 12:55 AM
$ABT Abbott Laboratories held the uptrend from 2020 lows and setting up for a potential bounce Average Returns When Weekly RSI <30: 1 Week: +0.43% 1 Month: +3.90% 3 Months: +9.26% 12 Months: +17.51%
0 · Reply
traderheadnyc
traderheadnyc Jan. 31 at 4:12 PM
$ABT this is one I may take a stake if it goes lower waiting still for lower has room to drop to -98-105
1 · Reply
OnlyFibs
OnlyFibs Jan. 31 at 4:20 AM
$ABT is a total battleground at $109! 🏥 Stock caught a 12% haymaker after 2026 guidance missed the mark, but with RSI in the gutter (<30) and 4 consecutive weeks of accumulation volume, the "oversold" spring is coiling. Is the $105 floor the ultimate bottom? 🛡️📉 🐂 Bulls: Must hold $105.27 and reclaim $115 to trigger the relief bounce. 🐻 Bears: Looking for a break below $105 to flush it toward the $93–$95 zone. Confirming level: $115.00 #ABT #AbbottLabs #Healthcare #StockMarket #hovdid
0 · Reply
Latest News on ABT
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

Feb 2, 2026, 9:30 AM EST - 1 day ago

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

10 Highest Rated Dividend Kings For Generations Of Income

Jan 29, 2026, 10:10 AM EST - 5 days ago

10 Highest Rated Dividend Kings For Generations Of Income

ABBV ABM ADM BDX BKH KMB KO

Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 9 days ago

Best Dividend Kings: January 2026

ABBV ABM ADM ADP AWR BDX BKH

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

Jan 25, 2026, 8:00 AM EST - 10 days ago

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

Jan 24, 2026, 7:30 AM EST - 11 days ago

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

Is The Fall In Abbott Stock Justified?

Jan 23, 2026, 9:35 AM EST - 11 days ago

Is The Fall In Abbott Stock Justified?

Abbott Laboratories: Buy This Dividend King On Sale Now

Jan 23, 2026, 7:25 AM EST - 12 days ago

Abbott Laboratories: Buy This Dividend King On Sale Now

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Jan 23, 2026, 6:43 AM EST - 12 days ago

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Abbott Laboratories Raised Prices, Prompting Sales Slump

Jan 22, 2026, 2:31 PM EST - 12 days ago

Abbott Laboratories Raised Prices, Prompting Sales Slump

Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript

Jan 22, 2026, 12:54 PM EST - 12 days ago

Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript

Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

Jan 22, 2026, 12:02 PM EST - 12 days ago

Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

Jan 22, 2026, 11:00 AM EST - 12 days ago

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

MRNA PG

Cramer's Mad Dash: Abbott Labs

Jan 22, 2026, 9:53 AM EST - 12 days ago

Cramer's Mad Dash: Abbott Labs

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Jan 22, 2026, 9:48 AM EST - 12 days ago

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Jan 22, 2026, 7:49 AM EST - 13 days ago

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Jan 22, 2026, 7:34 AM EST - 13 days ago

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Jan 22, 2026, 7:30 AM EST - 13 days ago

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings

Jan 22, 2026, 2:02 AM EST - 13 days ago

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings

Polen Focus Growth Portfolio  Q4 2025 Performance, Attribution & Portfolio Activity

Jan 21, 2026, 3:53 AM EST - 14 days ago

Polen Focus Growth Portfolio  Q4 2025 Performance, Attribution & Portfolio Activity

AAPL AMZN GOOG GOOGL ISRG IWB IWF

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Jan 20, 2026, 9:00 AM EST - 14 days ago

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Abbott Laboratories: Q4 Earnings On The Horizon

Jan 19, 2026, 7:30 AM EST - 16 days ago

Abbott Laboratories: Q4 Earnings On The Horizon

Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Jan 7, 2026, 9:17 AM EST - 27 days ago

Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Jan 7, 2026, 8:00 AM EST - 4 weeks ago

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Abbott hosts conference call for fourth-quarter earnings

Jan 5, 2026, 4:30 PM EST - 4 weeks ago

Abbott hosts conference call for fourth-quarter earnings

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Jan 5, 2026, 9:05 AM EST - 4 weeks ago

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 5 weeks ago

Best Dividend Aristocrats For January 2026

ABBV ADM ADP AFL ALB AMCR AOS

Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 5 weeks ago

Best Dividend Kings: December 2025

ABBV ABM ADM ADP AWR BDX BKH

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 5 weeks ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM AMGN AVGO BCPC BEN

Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise

Dec 24, 2025, 10:00 AM EST - 5 weeks ago

Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Dec 22, 2025, 9:00 AM EST - 6 weeks ago

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

Dec 18, 2025, 9:00 AM EST - 6 weeks ago

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

Abbott increases quarterly dividend for 54th consecutive year

Dec 12, 2025, 10:26 AM EST - 7 weeks ago

Abbott increases quarterly dividend for 54th consecutive year

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

Dec 11, 2025, 3:45 AM EST - 7 weeks ago

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

AI ASND AXON AZO CPRT DXCM HOOD

Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

Dec 8, 2025, 9:00 AM EST - 2 months ago

Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives

Dec 6, 2025, 8:45 PM EST - 2 months ago

University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives

Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement

Dec 4, 2025, 11:00 AM EST - 2 months ago

Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement

Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 2 months ago

Best Dividend Aristocrats For December 2025

ABBV ADM ADP AFL ALB AMCR AOS

Abbott issues US device correction for some glucose monitors over faulty readings risk

Nov 24, 2025, 11:08 AM EST - 2 months ago

Abbott issues US device correction for some glucose monitors over faulty readings risk

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

Nov 21, 2025, 8:30 PM EST - 2 months ago

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

EXAS

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Nov 20, 2025, 9:37 AM EST - 2 months ago

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

EXAS

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

Nov 20, 2025, 8:43 AM EST - 2 months ago

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

EXAS

Abbott to Acquire Exact Sciences for $21 Billion

Nov 20, 2025, 7:46 AM EST - 2 months ago

Abbott to Acquire Exact Sciences for $21 Billion

EXAS

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

Nov 20, 2025, 7:46 AM EST - 2 months ago

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

EXAS

Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

Nov 20, 2025, 7:36 AM EST - 2 months ago

Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

EXAS

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

Nov 20, 2025, 7:30 AM EST - 2 months ago

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

EXAS

Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

Nov 19, 2025, 4:27 PM EST - 2 months ago

Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

EXAS

Abbott is weighing takeover of Exact Sciences, Bloomberg News reports

Nov 19, 2025, 1:50 PM EST - 2 months ago

Abbott is weighing takeover of Exact Sciences, Bloomberg News reports

EXAS

Invesco Diversified Dividend Fund Q3 2025 Portfolio Positioning

Nov 12, 2025, 3:58 AM EST - 3 months ago

Invesco Diversified Dividend Fund Q3 2025 Portfolio Positioning

ALC AXP DD KDP KKR MRSH PG

10 Defensive Stocks with Market-Beating Yields

Nov 8, 2025, 1:10 PM EST - 3 months ago

10 Defensive Stocks with Market-Beating Yields

DG

MeridianSecurities
MeridianSecurities Feb. 4 at 11:28 AM
$ABT is a diversified healthcare giant with strong diagnostics and medical device businesses; FreeStyle Libre continues to excel.
0 · Reply
MiyagisenseiJr
MiyagisenseiJr Feb. 3 at 2:31 PM
$ABT wtf why is this dumping??
1 · Reply
MargieAdams1042
MargieAdams1042 Feb. 3 at 6:05 AM
$SAN $ABT Global diversification
0 · Reply
anachartanalyst
anachartanalyst Feb. 2 at 4:02 PM
$ABT https://anachart.com/wp-content/uploads/ana_temp/1770048106_soc-img.jpg
0 · Reply
erevnon
erevnon Feb. 2 at 3:11 PM
Barclays maintains Abbott Laboratories $ABT at Overweight and lowers the price target from $169 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Jas45z
Jas45z Feb. 2 at 3:11 PM
$ABT The stock recently touched a low near $105–$106 following its earnings report. Support Level: $105.00 is the critical floor. If it holds here, it forms a "double bottom" (a bullish reversal pattern). Initial Resistance: The first major hurdle is the $113.00 level (the previous low-end target). The Breakout Trigger: A high-volume move above $120.00 (reclaiming its 50-day moving average) would signal that the post-earnings sell-off is over and the primary uptrend has resumed.
0 · Reply
Bazzzigar
Bazzzigar Feb. 2 at 2:56 PM
$ABT few more
0 · Reply
PolycarpFX
PolycarpFX Feb. 2 at 12:55 AM
$ABT Abbott Laboratories held the uptrend from 2020 lows and setting up for a potential bounce Average Returns When Weekly RSI <30: 1 Week: +0.43% 1 Month: +3.90% 3 Months: +9.26% 12 Months: +17.51%
0 · Reply
traderheadnyc
traderheadnyc Jan. 31 at 4:12 PM
$ABT this is one I may take a stake if it goes lower waiting still for lower has room to drop to -98-105
1 · Reply
OnlyFibs
OnlyFibs Jan. 31 at 4:20 AM
$ABT is a total battleground at $109! 🏥 Stock caught a 12% haymaker after 2026 guidance missed the mark, but with RSI in the gutter (<30) and 4 consecutive weeks of accumulation volume, the "oversold" spring is coiling. Is the $105 floor the ultimate bottom? 🛡️📉 🐂 Bulls: Must hold $105.27 and reclaim $115 to trigger the relief bounce. 🐻 Bears: Looking for a break below $105 to flush it toward the $93–$95 zone. Confirming level: $115.00 #ABT #AbbottLabs #Healthcare #StockMarket #hovdid
0 · Reply
Jas45z
Jas45z Jan. 30 at 9:36 PM
$ABT why I loaded the boat on this dip? ABT) is a strong buy right now, imho, because it is a "Blue Chip" stock trading at a rare discount. The "Sale" Price: After a recent earnings dip in January 2026, the stock fell to ~$107 (near its 52-week low). Analysts see this as a bargain, with price targets averaging $136–$140 (roughly 27% upside). Massive New Growth: Abbott is acquiring Exact Sciences (Cologuard) for $21B. The deal, closing in Q2 2026, instantly makes Abbott a leader in the $60B cancer screening market. Tech Dominance: Their FreeStyle Libre glucose monitor continues to grow at double digits (15% growth in late 2025), remaining the gold standard in diabetes tech. Dividend Security: As a "Dividend King," Abbott recently raised its payout to $0.63/quarter (a ~7% hike). You get a reliable 2.35% yield while you wait for the stock price to recover. Not to mention? I’ve seen this price action in abbot several times!
2 · Reply
Enjoy_Life_Bro
Enjoy_Life_Bro Jan. 30 at 8:37 PM
$ABT come on. That drop past $108 didn’t shake me
0 · Reply
kb60521
kb60521 Jan. 30 at 7:21 PM
$ABT Hey......good call....I think we are getting there. Thanks.....
0 · Reply
topstockalerts
topstockalerts Jan. 30 at 7:12 PM
$ABT This setup keeps producing tradable moves. Buyers are consistently supporting price. Momentum remains favorable.
0 · Reply
kb60521
kb60521 Jan. 30 at 7:04 PM
$ABT Was nervous and not sure if we get to see 110 today. I am out.
1 · Reply
Hood16
Hood16 Jan. 30 at 6:30 PM
$ABT next Thursday they will report their financial numbers, 10Q document… up from here
0 · Reply
HydrogenH2
HydrogenH2 Jan. 30 at 5:58 PM
$ABT Next leg is...with US recession & stagflation !!
1 · Reply
nvda_wins_at_the_end
nvda_wins_at_the_end Jan. 30 at 5:52 PM
$ABT has made me sad.. I was holding my 300 shares, sold 3 of 106 calls for 90c.
0 · Reply
JasonJonathan
JasonJonathan Jan. 30 at 5:45 PM
$ABT BOOM! 🚀
0 · Reply
ST4Life
ST4Life Jan. 30 at 5:04 PM
$ABT I really do not get these people asking for a price target today, next week and so on. If you like ANY company and are bullish, stay invested and RELAX.
0 · Reply
jamesaz
jamesaz Jan. 30 at 4:59 PM
$ABT
1 · Reply
jamesaz
jamesaz Jan. 30 at 4:10 PM
$ABT
1 · Reply